Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of “Moderate Buy” by Analysts

Rapt Therapeutics (NASDAQ:RAPT) has received an average rating of “Moderate Buy” from the thirteen research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eight have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $50.50.

Several brokerages have recently commented on RAPT. Guggenheim began coverage on Rapt Therapeutics in a research report on Monday, October 27th. They issued a “buy” rating and a $70.00 price objective on the stock. JPMorgan Chase & Co. upped their price target on Rapt Therapeutics from $55.00 to $57.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 12th. Zacks Research lowered shares of Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapt Therapeutics in a report on Wednesday, October 8th. Finally, Barclays dropped their target price on shares of Rapt Therapeutics from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, November 7th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Dimensional Fund Advisors LP bought a new stake in shares of Rapt Therapeutics in the third quarter worth about $231,000. Bridgeway Capital Management LLC grew its holdings in Rapt Therapeutics by 32.0% during the 3rd quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company’s stock valued at $532,000 after buying an additional 5,000 shares in the last quarter. UBS Group AG increased its stake in Rapt Therapeutics by 680.3% in the 3rd quarter. UBS Group AG now owns 28,808 shares of the company’s stock worth $743,000 after acquiring an additional 25,116 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Rapt Therapeutics by 75.2% during the 3rd quarter. Millennium Management LLC now owns 39,278 shares of the company’s stock worth $1,013,000 after acquiring an additional 16,854 shares in the last quarter. Finally, Susquehanna International Group LLP boosted its position in shares of Rapt Therapeutics by 173.4% during the 3rd quarter. Susquehanna International Group LLP now owns 45,382 shares of the company’s stock valued at $1,170,000 after acquiring an additional 28,782 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Rapt Therapeutics Price Performance

Shares of NASDAQ:RAPT opened at $33.81 on Friday. The company has a market capitalization of $936.88 million, a P/E ratio of -3.06 and a beta of 0.43. Rapt Therapeutics has a 1-year low of $5.67 and a 1-year high of $42.39. The firm’s 50 day simple moving average is $30.86 and its two-hundred day simple moving average is $19.44.

Rapt Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.23. On average, sell-side analysts anticipate that Rapt Therapeutics will post -2.14 earnings per share for the current fiscal year.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.